Background: Direct-acting antivirals allow efficient and safe treatment of hepatitis C
| INTRODUC TI ON
Since the introduction of directly acting antiviral drugs (DAA), treatment of chronic hepatitis C (HCV) before and after liver transplantation (LT) has become an effective procedure with a low adverse event profile. According to current recommendations, the large majority of HCV-positive patients can be simply cured by interferon-free regimens with impressive sustained virological response rates (SVR) up to 100%, depending on the viral genotype and stage of hepatic fibrosis. [1] [2] [3] The interferon era
shows, that tissue inflammation immediately stops and fibrosis may reverse toward lower stages several years after a successful antiviral treatment (AVT) in liver transplant patients. [4] [5] [6] It seems to be expectable, that the same phenomenon appears in patients treated with DAAs. However, that has not been reported yet. Furthermore, chronic HCV-infection is currently understood as a systemic disease and is associated with a whole variety of primarily extrahepatic diseases such as diabetes mellitus (DM), depression, kidney disorders (membranoproliferative glomerulonephritis), Non-Hodgkin-lymphomas, osteoporosis and non-hepatic malignancies. [7] [8] [9] [10] It has been reported and confirmed in a detailed meta-analysis that HCV promotes the development of DM.
10,11
Although many antiviral regimens are approved for treatment of patients with chronic hepatitis-C before and after LT, some important questions remain to be addressed. The majority of antiviral regimens are based on sofosbuvir (SOF) and have a limitation in patients with severe kidney dysfunction. Data about the usage, dosing, efficacy, and safety for patients with chronic kidney disease (CKD) are still limited. [12] [13] [14] A ritonavir-boosted paritaprevir-, ombitasvir-, and dasabuvir-based regimens are approved irrespectively of kidney function, but their usage in transplant patients is not favorable due to severe drug-drug interactions especially with calcineurin inhibitors (CNI) compared to SOF. 15 SOF-containing therapies are not recommended for patients with a glomerular filtration rate (GFR) <30 mL/min according to the guidelines of EASL/AASLD. 16 The main explanation for this limitation is the renal excretion of the mainly inactive SOF-metabolite GS-331007. 16 According to the literature, this topic is not well studied yet. There are several reports of small series of patients treated with a reduced dose of SOF, providing remarkable results for efficacy and safety. 12, 17, 18 Based on our own experience, a full dose of SOF combined with a second antiviral substance depending on the viral genotype and transplant fibrosis stage is an effective and safe procedure to treat recurrent HCV-infection after LT despite the current recommendations for patients with severe CKD. 16, 19 We performed a retrospective analysis of AVT after LT focusing on kidney function to deliver additional data from clinical practice. Primary endpoint of this analysis was the evaluation of kidney function after AVT. Secondary endpoints were the assessment of extrahepatic manifestation of HCV-infection by DM and the histopathological changes in terms of inflammation, content of fat, and fibrosis stage in the graft. 
| PATIENTS AND ME THODS

| Demographics
| Antiviral treatment
| Histology
All patients underwent a routine biopsy directly before treatment ini- 
| Diabetes
Diabetes mellitus was defined as insulin-dependent type II diabetes mellitus. There were 32 patients diagnosed with DM at the moment of treatment initiation and 68 patients had no diabetes or no diagnosis of diabetes had been made before. Median Hb1Ac was 5.6% (3.8-15.6) in the entire cohort. Mean Hb1Ac in the diabetes subgroups was 7.2% (2.3). Differences in Hb1Ac and cumulative daily insulin dose of short-and long-acting insulin before and after AVT were compared with each other. Weight in kg was evaluated at the beginning, end and 12 weeks after AVT.
| Kidney function
Renal dysfunction and CKD were defined according to the classification of the National Kidney Foundation from 2002 (normal to 
| RE SULTS
| Antiviral treatment
All patients achieved SVR and no relapse was identified in the presented cohort during the further follow-up of 30.6 months. The median age of the patients was 63.9 years. AVT with DAAs was initiated 8 (0-25) years after LT in median. A total of 82% of the patients were not treatment-naïve and had undergone IFN-based treatment before. SOF-related adverse events did not occur during and after the treatment except with patients additionally treated with RBV.
There were especially no episodes of rejection detected during and after AVT. In more than 50.0%, RBV dose had to be reduced and in 40.0% even stopped because of adverse events. 
| Histology
| Diabetes
The proportion of patients with diabetes (32%) did not significantly change after the end of AVT. However, two patients did not require insulin anymore after AVT. Further changes in anti-diabetic treatment were not observed. HbA1c in patients without diabetes did not demonstrate any difference as expected during and after the AVT (5.5% vs 5.5%; P = 0.442). However, Hb1Ac declined in patients with diabetes after AVT compared to the situation before (6.4% vs Generally, impaired renal failure (GFR < 30 mL/min) appears in patients undergoing LT within three periods. The authors concluded that a preexisting impaired renal function worsens after AVT with SOF. 13 In spite of principally comparable SVR, patients after LT are at a different risk for impaired kidney function. Immunosuppressive medication may frequently cause DM, arterial hypertension, obesity and renal dysfunction. That contribute to the reduction in GFR aside from further potentially nephrotoxic medication of AVT such as RBV. The negative impact of RBV in terms of adverse events is frequently observed in LT-patients as published before.
1,28
The limitation of this study regarding the impact on kidney function is the absence of a control group and the limited number of patients with severe and end stage kidney disease. The observation of a significant decline of GFR in patients with a slight and mild kidney dysfunction might be attributed to the natural decline of GFR. The results were obtained from a well-characterized and homogenous liver transplant cohort treated for HCV-recurrence predominantly with a simple, robust and reliable therapy without significant adverse events associated with SOF.
In conclusion, there is a whole variety of positive development in LT-patients after successful AVT with SOF-based regimen including a significant improvement of inflammation and fibrosis based on liver histology, a significant decrease in daily insulin dose required to control diabetes and no significant impairment of kidney function 12 weeks after AVT in LT-patients.
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